IN8bio, Inc.

NasdaqCM:INAB Stock Report

Market Cap: US$10.8m

IN8bio Past Earnings Performance

Past criteria checks 0/6

IN8bio's earnings have been declining at an average annual rate of -5%, while the Biotechs industry saw earnings growing at 34.1% annually.

Key information

-5.01%

Earnings growth rate

42.40%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-101.66%
Net Marginn/a
Last Earnings Update30 Jun 2026

Recent past performance updates

No updates

Recent updates

Analysis Article • Aug 06

IN8bio (NASDAQ:INAB) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 03

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 04

Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 26

Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 12

Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 30

IN8bio gains 53% as H.C. Wainwright initiates with Buy

The share of clinical-stage biotech IN8bio, Inc. (NASDAQ:INAB) jumped ~53% on Tuesday after H.C. Wainwright started its coverage with a Buy recommendation citing an underappreciated therapeutic platform and an attractive entry point for long-term investors. INAB, focused on cancer treatments, is undervalued at its current valuation of $48M, the analyst noted, pointing to the advantages of the company’s gamma-delta T cell therapies over traditional chimeric antigen receptor treatments. With a $14 per share target on the stock, H.C. Wainwright projects that INAB’s cell therapy candidates, including the lead asset INB-200 and pre-clinical drugs, will reach the market in 2025, growing to a ~$411M potential on a risk-adjusted basis by 2030. The firm’s bullish view comes more than a year after INAB's IPO, which generated $40M in gross proceeds.
Seeking Alpha • Aug 19

IN8bio raises additional funds from underwriter of stock offering

IN8bio (NASDAQ:INAB) stock rose ~5% on Aug. 19 after the company said that the underwriter of its public offering partially exercised its option to buy an additional ~268.95K shares at $1.90 apiece for ~$0.5M. In total, the company sold ~5.66M shares and raised gross proceeds of ~$10.75M. H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
Seeking Alpha • Aug 12

IN8bio prices $10.25M stock offering

IN8bio (NASDAQ:INAB) has priced an underwritten public offering of 5,394,737 shares of its common stock at a public offering price of $1.90/share for an expected gross proceeds of ~$10.25M. Underwriter are granted a 30-day option to purchase up to an additional 657,894 shares of common stock at the public offering price. Offering is expected to close on or about August 16, 2022. The gross proceeds to IN8bio from the offering are e.
Analysis Article • Jun 04

We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Feb 13

IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 29

IPO Update: IN8bio Aims For Downsized IPO

IN8bio has filed proposed terms for a $44 million IPO. The firm is developing treatments for various blood cancers. INAB is still at a very early stage of development and the IPO may be more suited to institutional investors; I'll watch it from the sidelines.

Revenue & Expenses Breakdown

How IN8bio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:INAB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 260-19910
31 Mar 260-191010
31 Dec 250-191010
30 Sep 250-211011
30 Jun 250-241112
31 Mar 250-271215
31 Dec 240-301317
30 Sep 240-321318
30 Jun 240-321418
31 Mar 240-311417
31 Dec 230-301417
30 Sep 230-301416
30 Jun 230-301417
31 Mar 230-301416
31 Dec 220-291414
30 Sep 220-271413
30 Jun 220-231310
31 Mar 220-18108
31 Dec 210-1577
30 Sep 210-1256
30 Jun 210-1146
31 Mar 210-1146
31 Dec 200-1035
30 Sep 200-935
30 Jun 200-834
31 Mar 200-633
31 Dec 190-632

Quality Earnings: INAB is currently unprofitable.

Growing Profit Margin: INAB is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: INAB is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.

Accelerating Growth: Unable to compare INAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).

Return on Equity

High ROE: INAB has a negative Return on Equity (-101.66%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 11:38
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IN8bio, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Swayampakula RamakanthH.C. Wainwright & Co.
Soumit RoyJonesTrading Institutional Services, LLC